A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

Completed · Phase 2

Conditions studied: Infected Corneal Ulcers, Bacterial Keratitis, Corneal Ulcer, Childhood Blindness

In brief

Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.

Key facts

Study ID

NCT00386958

Run by

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

People needed

172

Starts

2002-11-01

Expected to finish

2006-01-01

Last updated by the study team

2016-08-23

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of untreated bacterial corneal ulcer that began within 14 days of presentation to the study center.
• Corneal ulcer size is 2 mm-8 mm. in diameter, and does not extend to the limbus.

You may not qualify if…

• Topical or systemic antimicrobial or immunosuppressant therapy within 14 days of presentation to the study center.
• Corneal ulcer smear and culture fail to show the presence of bacteria.
• Allergic history to povidone-iodine, iodine or any components of Neosporin.
• Dacrocystitis, neurotropic or exposure keratitis, keratitis sicca, positive HIV status, and legal blindness in the unaffected eye.

Where it is running

• Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center — Torrance, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.